vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPriority Technology Holdings, Inc.（PRTH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Priority Technology Holdings, Inc.の直近四半期売上が大きい（$247.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 3.6%、差は9.7%）。Priority Technology Holdings, Inc.の前年同期比売上増加率が高い（8.8% vs -1.8%）。Priority Technology Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$30.9M vs $24.6M）。過去8四半期でPriority Technology Holdings, Inc.の売上複合成長率が高い（9.6% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Priority Technology Holdings, Inc.は情報技術分野に注力する企業で、コンピューターや通信システムをはじめとする情報関連機器を軸に、情報の作成、処理、保存、検索、伝送といった情報技術関連の応用サービスを手がけ、コンピューターサイエンスと工学技術を基盤に事業を展開しています。
AMPH vs PRTH — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $247.1M |
| 純利益 | $24.4M | $8.9M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 13.6% |
| 純利益率 | 13.3% | 3.6% |
| 売上前年比 | -1.8% | 8.8% |
| 純利益前年比 | -35.7% | 23.9% |
| EPS（希薄化後） | $0.51 | $0.10 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $247.1M | ||
| Q3 25 | $191.8M | $241.4M | ||
| Q2 25 | $174.4M | $239.8M | ||
| Q1 25 | $170.5M | $224.6M | ||
| Q4 24 | $186.5M | $227.1M | ||
| Q3 24 | $191.2M | $227.0M | ||
| Q2 24 | $182.4M | $219.9M | ||
| Q1 24 | $171.8M | $205.7M |
| Q4 25 | $24.4M | $8.9M | ||
| Q3 25 | $17.4M | $27.6M | ||
| Q2 25 | $31.0M | $10.9M | ||
| Q1 25 | $25.3M | $8.3M | ||
| Q4 24 | $38.0M | $7.2M | ||
| Q3 24 | $40.4M | $10.6M | ||
| Q2 24 | $37.9M | $994.0K | ||
| Q1 24 | $43.2M | $5.2M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 13.6% | ||
| Q3 25 | 13.2% | 15.6% | ||
| Q2 25 | 24.2% | 15.6% | ||
| Q1 25 | 21.9% | 14.5% | ||
| Q4 24 | 24.2% | 15.0% | ||
| Q3 24 | 29.8% | 16.8% | ||
| Q2 24 | 30.3% | 15.1% | ||
| Q1 24 | 27.9% | 13.6% |
| Q4 25 | 13.3% | 3.6% | ||
| Q3 25 | 9.0% | 11.4% | ||
| Q2 25 | 17.8% | 4.5% | ||
| Q1 25 | 14.8% | 3.7% | ||
| Q4 24 | 20.4% | 3.2% | ||
| Q3 24 | 21.1% | 4.7% | ||
| Q2 24 | 20.8% | 0.5% | ||
| Q1 24 | 25.1% | 2.5% |
| Q4 25 | $0.51 | $0.10 | ||
| Q3 25 | $0.37 | $0.34 | ||
| Q2 25 | $0.64 | $0.14 | ||
| Q1 25 | $0.51 | $0.10 | ||
| Q4 24 | $0.74 | $-0.05 | ||
| Q3 24 | $0.78 | $0.07 | ||
| Q2 24 | $0.73 | $-0.23 | ||
| Q1 24 | $0.81 | $-0.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $77.2M |
| 総負債低いほど良い | $608.7M | $1.0B |
| 株主資本純資産 | $788.8M | $-100.4M |
| 総資産 | $1.6B | $2.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $77.2M | ||
| Q3 25 | $276.2M | $57.0M | ||
| Q2 25 | $231.8M | $50.6M | ||
| Q1 25 | $236.9M | $47.6M | ||
| Q4 24 | $221.6M | $58.6M | ||
| Q3 24 | $250.5M | $41.1M | ||
| Q2 24 | $217.8M | $34.6M | ||
| Q1 24 | $289.6M | $34.3M |
| Q4 25 | $608.7M | $1.0B | ||
| Q3 25 | $608.6M | $997.5M | ||
| Q2 25 | $607.7M | $917.0M | ||
| Q1 25 | $603.9M | $918.9M | ||
| Q4 24 | $601.6M | $920.9M | ||
| Q3 24 | $596.4M | $808.1M | ||
| Q2 24 | $586.9M | $809.0M | ||
| Q1 24 | $594.0M | $631.4M |
| Q4 25 | $788.8M | $-100.4M | ||
| Q3 25 | $776.7M | $-110.3M | ||
| Q2 25 | $757.5M | $-146.1M | ||
| Q1 25 | $751.3M | $-158.3M | ||
| Q4 24 | $732.3M | $-166.8M | ||
| Q3 24 | $727.7M | $-165.8M | ||
| Q2 24 | $713.3M | $-172.1M | ||
| Q1 24 | $672.4M | $-159.9M |
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.6B | $2.0B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.6B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $36.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $30.9M |
| FCFマージンFCF / 売上 | 13.4% | 12.5% |
| 設備投資強度設備投資 / 売上 | 4.5% | 2.4% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 4.12× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $75.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $36.8M | ||
| Q3 25 | $52.6M | $36.1M | ||
| Q2 25 | $35.6M | $17.1M | ||
| Q1 25 | $35.1M | $10.0M | ||
| Q4 24 | $29.0M | $23.8M | ||
| Q3 24 | $60.0M | $19.8M | ||
| Q2 24 | $69.1M | $28.7M | ||
| Q1 24 | $55.3M | $13.3M |
| Q4 25 | $24.6M | $30.9M | ||
| Q3 25 | $47.2M | $30.1M | ||
| Q2 25 | $25.0M | $9.2M | ||
| Q1 25 | $24.4M | $4.9M | ||
| Q4 24 | $16.6M | $19.1M | ||
| Q3 24 | $46.2M | $14.5M | ||
| Q2 24 | $63.1M | $23.6M | ||
| Q1 24 | $46.5M | $6.7M |
| Q4 25 | 13.4% | 12.5% | ||
| Q3 25 | 24.6% | 12.5% | ||
| Q2 25 | 14.3% | 3.8% | ||
| Q1 25 | 14.3% | 2.2% | ||
| Q4 24 | 8.9% | 8.4% | ||
| Q3 24 | 24.1% | 6.4% | ||
| Q2 24 | 34.6% | 10.7% | ||
| Q1 24 | 27.1% | 3.3% |
| Q4 25 | 4.5% | 2.4% | ||
| Q3 25 | 2.8% | 2.5% | ||
| Q2 25 | 6.1% | 3.3% | ||
| Q1 25 | 6.3% | 2.3% | ||
| Q4 24 | 6.7% | 2.0% | ||
| Q3 24 | 7.2% | 2.3% | ||
| Q2 24 | 3.3% | 2.3% | ||
| Q1 24 | 5.1% | 3.2% |
| Q4 25 | 1.35× | 4.12× | ||
| Q3 25 | 3.03× | 1.31× | ||
| Q2 25 | 1.15× | 1.57× | ||
| Q1 25 | 1.39× | 1.20× | ||
| Q4 24 | 0.76× | 3.29× | ||
| Q3 24 | 1.48× | 1.87× | ||
| Q2 24 | 1.82× | 28.87× | ||
| Q1 24 | 1.28× | 2.56× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRTH
セグメントデータなし
